Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript
Summarize this article with:
SA Transcripts157.36K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment December 15, 2025 8:00 AM EST Company Participants Joseph Oliveto - CEO, President & DirectorDavid Bharucha - Chief Medical OfficerLorenz Muller - Chief Commercial OfficerAmit Hasija - CFO & Executive VP of Corporate Development Conference Call Participants Michael Wood - Lifesci Advisors, LLCRitu Baral - TD Cowen, Research DivisionEdward Tenthoff - Piper Sandler & Co., Research DivisionZhengxi Sun - Wells Fargo Securities, LLC, Research DivisionBrandon Folkes - H.C. Wainwright & Co, LLC, Research DivisionGeorgia Bank - Jefferies LLC, Research Division Presentation Operator Greetings. Welcome to Milestone Pharmaceuticals CARDAMYST FDA Approval Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to Michael Wood at LifeSci Advisors. Thank you. You may begin. Michael WoodLifesci Advisors, LLC Thank you, operator. Good morning, everyone, and welcome to Milestone's conference call and webinar to discuss the FDA approval of CARDAMYST nasal spray. On a Friday evening, the company issued a press release on the approval. This can be accessed on the News & Events page of the company's corporate website at milestonepharma.com. During today's call, the company will be making certain forward-looking statements. I will refer you to the safe harbor statement here on Slide 2. A description of potential risks and uncertainties can also be found in today's press release and on the company's latest SEC disclosure documents. The agenda for today's call is outlined here. Joe Oliveto, Milestone's President and CEO, will begin with opening remarks, including covering the basics of the product label. He will be followed by Dr. David Bharucha, the company's Chief Medical Officer, to discuss the clinician's perspective relative to the medical need. Lorenz Muller, Chief Commercial Officer, will then talk about the launch plans and Joe will conclude before we open